with chronic cutaneous (discoid) lupus erythematosus. 5 The finding of deep perifollicular inflammation in the reticular dermis and even the subcutaneous tissue should not discourage dermatopathologists from making a diagnosis of LPP and especially FFA.
Hypopigmentation in frontal fibrosing alopecia
To the Editor: Frontal fibrosing alopecia (FFA), a variant of lichen planopilaris (LPP), is a progressive scarring process that clinically presents as symmetrical frontoparietal hair loss. 1 Skin in the affected areas is thin, hypopigmented, and with increased vascular prominence. 2 This partial or complete loss of pigmentation can be appreciated on examination with a Wood's lamp to explore the nature of the observed hypopigmentation (Fig 1) .
Melanocyte counts and epidermal thickness were compared in scalp biopsy specimens obtained from patients with FFA, LPP, and controls. Histologic scalp specimens from patients with scarring alopecias (FFA, n ¼ 5; LPP, n ¼ 4) and controls (n ¼ 10) were evaluated for epidermal melanocyte counts using Melan-A and tyrosinase immunohistochemical stains. The melanocyte count was evaluated by 2 independent dermatopathologists (MV, NAM) blinded to the diagnoses. Melanocytes were counted in 3 consecutive high-power fields (HPFs). Two-tailed unpaired t tests with an alpha of 0.05 were used during the analysis of data.
The FFA melanocyte counts were found to be lower than the counts seen in biopsy specimens obtained from patients with LPP and controls. The mean epidermal melanocyte counts in FFA scalps were 2.7 6 1.3 ( per HPF) with Melan-A stain and 1.5 6 0.7 ( per HPF) with tyrosinase stain (Fig 2) . Control group means were 7.9 6 3.5 and 4.9 6 3.7, respectively; in the LPP group, means were 7.3 6 2.7 and 4.6 6 2.8. Melan-A staining revealed statistically significant differences between FFA and LPP (P ¼ .012) and between the FFA and control groups (P ¼ .006). There was also a significant difference between the FFA and LPP groups with tyrosinase stain (P ¼ .043). To explore epidermal thickness in patients with LPP and FFA, histologic measurements were obtained. The average epidermal thickness was highest in patients with LPP (0.155 mm; P ¼ .018) followed by controls (0.116 mm; P ¼ .085) and patients with FFA (0.072 mm).
The focus of our study was to evaluate the hypopigmentation and atrophy seen clinically in FFA. Our findings suggest that a lower melanocyte count is associated with hypopigmentation observed clinically. Interestingly, this clinical finding is not overtly appreciated in LPP cases where melanocyte counts were similar to the controls, which was also confirmed on histology. This may reflect a possible difference in these 2 types of scarring alopecia. Both LPP and FFA are diseases characterized by inflammatory infiltration of the follicular bulge region. The underlying immune privilege collapse and T H 1-biased cytotoxic T cell activation in hair follicles involving mechanisms of disease is centered at the infundibulum and bulge. 3 We also found a reduction in epidermal thickness in the biopsy specimens of patients with FFA compared to patients with LPP (P ¼ .018). Similar findings of epidermal atrophy on histologic evaluation have been described in a previous series of patients with FFA. 4 While cytokine-mediated responses might play a role in triggering these changes, further causative analysis must be performed.
Our study provides an association between hypopigmentation seen in patients with FFA and by decreased epidermal melanocyte numbers on histology. Future studies should examine the pathophysiologic connection between the loss of epidermal melanocytes and hair follicles in FFA. Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients
To the Editor: Pattern hair loss is common in the general population, affecting 50% of men by age 50 1 and 30% of women by age 30, 2 with prevalence increasing with age. Despite the high prevalence, few treatment options with established safety and efficacy are available. Topical minoxidil, oral finasteride, anti-androgen therapy are commonly used 1 but require indefinite use and rarely accomplish complete regrowth, leaving many patients dissatisfied. 3 Hair loss is associated with substantial psychological distress that is particularly severe for women. In a study of 60 men and 96 women with pattern hair loss, 52% of women and 27% of men were very to extremely upset about their hair loss. 3 There is a paucity of information regarding topical camouflaging agents used to conceal hair loss. To the authors' knowledge, there is only one study of 40 patients investigating the effect of these products on patients' confidence, which was reported to improve. 4 In the present study, we sought to better understand the use of these products and their impact on patients' appearance and self-esteem.
A link to a 12-query, anonymous, IRBapproved survey, created using Survey Monkey, was posted on various Internet hair loss blogs. Individuals completed the survey voluntarily and were included if they were at least 18 years old with self-reported hair loss. In total, 359 individuals responded. Of these, 348 (97%) reported hair loss, and 281 (78%) had seen a physician about their hair loss. Camouflaging agents were used by 283 (79%), and the products chosen were most often hair-building fibers (59%), followed by hairpieces and wigs (51%). Forty-three percent used topical concealing agents daily. Use of these products improved appearance in 216 (82%) respondents, and 173 (71%) reported improved selfesteem.
Patients gave 316 responses to open-ended questions asking about their topical concealer experiences and preferences. Topical concealers worked well for minimal-to-moderate hair loss, but a hairpiece was preferred as hair loss progressed. Negative aspects of topical concealers were messiness ( particularly on clothing, bedding, and bathroom surfaces), time for application, expense, itchiness, anxiety over concealers being conspicuous or unnatural looking, and the removing effects of wind, rain, and swimming. Many believed the positive effects on appearance and self-confidence outweighed these negative aspects.
Although most respondents saw a physician for hair loss, only 8 of 270 respondents (3%) reported learning about concealing products from their physician. We attempted to contact 20 regional dermatologists specializing in hair loss to ascertain if these products were recommended; only 4 responded, and none recommended these products, confirming our results. This experience further suggests that patients might have difficulty obtaining information before or after an appointment.
Products to conceal hair loss are readily available online from dozens of retailers. Table I provides information about types of products and their cost. 5 Pattern hair loss is one of the most common chronic problems encountered by dermatologists. 1 Given the significant psychologic morbidity in patients with hair loss and the limited effective treatment options, the authors believe that physicians should educate their patients about topical concealing agents, which can serve as an adjunct to medical therapy and improve psychologic well-being.
Limitations of this study include the potential for survey bias and recall bias from self-reporting patients.
